The Role of Metabolic Disorders in the Development of Waxy Flexibility in Patients with Catatonic Schizophrenia
Abstract
-
1. Sneller MH, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, et al. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Front Psychiatry. 2021;12:625935.
2. Lang X, Zhou Y, Zhao L, Gu Y, Wu X, Zhao Y, et al. Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naive schizophrenia patients. Psychoneuroendocrinology. 2021;132:105344.
3. Li Z, Wang S, Chen Y, Wu X, Gu Y, Lang X, et al. Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population. Int J Neuropsychopharmacol. 2021;24(10):798-807.
4. Zheng W, Jiang WL, Zhang X, Cai DB, Sun JW, Yin F, et al. Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies. Psychiatr Q. 2022;93(1):137-49.
5. Molina JD, Avila S, Rubio G, López-Muñoz F. Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players. Curr Pharm Des. 2021;27(39):4049-61.
6. Garrido-Torres N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, Ruiz MJ, Gómez-Revuelta M, et al. Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort. Schizophr Res. 2022;246:277-85.
7. Garrido-Torres N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, Ruiz MJ, Gómez-Revuelta M, et al. Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort. Schizophr Res. 2022;246:277-85.
8. Mednova IA, Chernonosov AA, Kornetova EG, Semke AV, Bokhan NA, Koval VV, et al. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome. Metabolites. 2022;12(9):850.
9. DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021;11(6):311-9.
2. Lang X, Zhou Y, Zhao L, Gu Y, Wu X, Zhao Y, et al. Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naive schizophrenia patients. Psychoneuroendocrinology. 2021;132:105344.
3. Li Z, Wang S, Chen Y, Wu X, Gu Y, Lang X, et al. Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population. Int J Neuropsychopharmacol. 2021;24(10):798-807.
4. Zheng W, Jiang WL, Zhang X, Cai DB, Sun JW, Yin F, et al. Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies. Psychiatr Q. 2022;93(1):137-49.
5. Molina JD, Avila S, Rubio G, López-Muñoz F. Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players. Curr Pharm Des. 2021;27(39):4049-61.
6. Garrido-Torres N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, Ruiz MJ, Gómez-Revuelta M, et al. Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort. Schizophr Res. 2022;246:277-85.
7. Garrido-Torres N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, Ruiz MJ, Gómez-Revuelta M, et al. Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort. Schizophr Res. 2022;246:277-85.
8. Mednova IA, Chernonosov AA, Kornetova EG, Semke AV, Bokhan NA, Koval VV, et al. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome. Metabolites. 2022;12(9):850.
9. DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021;11(6):311-9.
| Files | ||
| Issue | Articles in Press | |
| Section | Letter to the Editor | |
| Keywords | ||
| Metabolic Disorders , Waxy Flexibility ,Catatonic Schizophrenia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Abdollahi R. The Role of Metabolic Disorders in the Development of Waxy Flexibility in Patients with Catatonic Schizophrenia. Iran J Psychiatry. 2025;:1-2.
